{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T06:53:23Z","timestamp":1768892003682,"version":"3.49.0"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejca.2025.116156","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:09:26Z","timestamp":1764605366000},"page":"116156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Successful treatment of durvalumab-induced psoriasis in an HBV-positive lung cancer patient with Risankizumab: A novel case report"],"prefix":"10.1016","volume":"232","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1925-1243","authenticated-orcid":false,"given":"Davide","family":"Fattore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca Futura","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3869-2623","authenticated-orcid":false,"given":"Gianluca","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1803-2046","authenticated-orcid":false,"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejca.2025.116156_bib1","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/jdv.17855","article-title":"European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement","volume":"36","author":"Apalla","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.ejca.2025.116156_bib2","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jaad.2020.08.137","article-title":"et a. Immune checkpoint-mediated psoriasis: a multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group","volume":"84","author":"Nikolaou","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.ejca.2025.116156_bib3","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.3390\/jcm13071940","article-title":"Biological therapy for psoriasis in cancer patients: an 8-year retrospective real-life study","volume":"13","author":"Battista","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.ejca.2025.116156_bib4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2012.10.003","article-title":"IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer","volume":"79","author":"Baird","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2025.116156_bib5","article-title":"Dermatologic immune-related adverse events: It is time for a game change!","author":"Fattore","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925010421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925010421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T17:40:38Z","timestamp":1768844438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925010421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":5,"alternative-id":["S0959804925010421"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116156","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful treatment of durvalumab-induced psoriasis in an HBV-positive lung cancer patient with Risankizumab: A novel case report","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116156","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116156"}}